Search clinical trials for: Dolutegravir

Total 288 results

University Hospital, Tours
University Hospital, Rouen; Central Hospital, Nancy, France; Poitiers University... and other collaborators

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (TRULIGHT)

HIV

France
Centre Hospitalier Régional d'Orléans

Terminated

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients (MONCAY)

HIV

France
University of Zurich

Unknown

Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection

Treatment Efficacy | Monotherapy | Dolutegravir | Primary HIV Infection

Switzerland
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline

Terminated

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

HIV Infections

United States, Taiwan, Peru, Canada, Thailand, Australia, Puerto Rico, Russian Federation, Argentina, Mexico, Colombia, South Africa, Chile
ViiV Healthcare
GlaxoSmithKline

Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Infection, Human Immunodeficiency Virus

Germany
Juan A. Arnaiz

Unknown

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

Acquired Immune Deficiency Syndrome Virus

Spain
Asociacion para el Estudio de las Enfermedades...

Completed

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression (DOLBI)

HIV Infection

Spain
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir (VIKING-4)

HIV Infections

United States
St Stephens Aids Trust
ViiV Healthcare

Completed

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (SSAT073)

HIV

United Kingdom
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico
St Stephens Aids Trust

Completed

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

HIV

Germany, Spain, France, United Kingdom, Belgium, Italy
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

HIV

United Kingdom
Military Hospital of Tunis

Unknown

Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock

Septic Shock

Tunisia
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (ING112276)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Germany, Italy, Russian Federation
University of Melbourne
The Alfred; ViiV Healthcare

Completed

Dolutegravir Impact on Residual Replication (DIORR)

HIV

Australia
Calmy Alexandra

Completed

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients (MONODO)

Human Immunodeficiency Virus | Treatment Efficacy | Monotherapy | Dolutegravir

Switzerland
St. Stephens Clinical Research

Unknown

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers (RADIO)

Tuberculosis | HIV-1-infection
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Drug Interaction Study With Efavirenz

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

HIV-1 Infection

France
Fundación Huésped
ViiV Healthcare

Completed

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study (PADDLE)

HIV-1 Infection

Argentina
ViiV Healthcare

Completed

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Infection, Human Immunodeficiency Virus

United States
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
Hospital Universitari Vall d'Hebron Research Institute
University Hospital, Ghent; IrsiCaixa

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

HIV-1

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Relative Bioavailability Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
Chiesi Farmaceutici S.p.A.

Completed

FACTO Study (Foster® As Complete Treatment Option) (FACTO)

Asthmatic Patients

Spain, France, Germany, Netherlands
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

Healthy Subjects

United States
University Hospital, Caen

Unknown

Adherence to Dolutegravir and Outcome (DOLUTECAPS)

HIV

France
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Infection, Human Immunodeficiency Virus

United States, Canada, Puerto Rico
University of Colorado, Denver

No longer available

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

Human Immunodeficiency Virus (HIV)

United States
University of Liverpool
ViiV Healthcare; Makerere University

Completed

Dolutegravir Interactions With Artemisinin-based Combination Therapies (DolACT)

HIV | Malaria

Uganda
Kuopio University Hospital

Completed

Stepping Down of Asthma Medication in Controlled Asthma

Asthma

Finland
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers

HIV

United Kingdom
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Andrew Carr
ViiV Healthcare Australia Pty. Ltd

Completed

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (dPEP)

Human Immunodeficiency Virus

Australia
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

HIV-1 Infection

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease

HIV

Spain
University Hospital, Strasbourg, France

Unknown

Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation

HIV-1 Infection

France
Nantes University Hospital

Withdrawn

Dolutegravir + Rilpivirine Switch Study (DORISS) (DORISS)

HIV Infection | HAART-treated | Virologically Controlled

France

Search clinical trials for: Dolutegravir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations